Anticardiolipin antibodies in various diseases in Taiwan: A retrospective analysis

Lupus

Volumn 12, Issue 10, 2003, Pages 747-753

  Tsai, M H ^a   Tsai, W P ^a   Liao, S T ^b   Liou, Lieh Bang ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b JEN AI HOSPITAL   (Taiwan)

Author keywords

Anticardiolipin antibodies; Autoimmune diseases; Pregnancy loss; Stroke; Vascular thrombosis

Indexed keywords

AUTOANTIBODY; CARDIOLIPIN ANTIBODY;

ADOLESCENT; ADULT; AGED; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; AUTOIMMUNE DISEASE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CHILD; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PREGNANCY; PREMATURITY; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; STROKE; THROMBOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTICARDIOLIPIN; CEREBROVASCULAR ACCIDENT; CHILD; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PREGNANCY; PREGNANCY COMPLICATIONS; RETROSPECTIVE STUDIES; RISK FACTORS; SEROEPIDEMIOLOGIC STUDIES; TAIWAN; THROMBOSIS;

EID: 0142023743     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203303lu459oa     Document Type: Article

References (56)

1. Asherson RA, Harris EN. Anticardiolipin antibodies-clinical associations. Postgrad Med J 1986; 62: 1081-1087.
2. Hughes GRV. The antiphospholipid syndrome: Ten years on. Lancet 1993; 342: 341-344.
3. Briley DP, Coull BM, Goodnight SH Jr. Neurological disease associated with antiphospholipid antibodies. Ann Neurol 1989; 25: 221-227.
4. Fields RA, Toubbeh H, Searles RP, Bankhurst AD. The prevalence of anticardiolipin antibodies in a healthy elderly population and its association with antinuclear antibodies. J Rheumatol 1989; 16: 623-625.
5. Shi W, Krilis SA, Chong BH, Gordon S, Chesterman CN. Prevalence of lupus anticoagulant and anticardiolipin antibodies in a healthy population. Aust NZ J Med 1990; 20: 231-236.
6. Jones HW, Ireland R, Sennldi G et al. Antiphospholipid antibodies in patients with Malaysia with systemic lupus erythematosus. Ann Rheum Dis 1991; 50: 173-175.
7. Picillo U, Migliaresi S, Marcialis MR, Longobardo A, La Palombara F, Tirri G. Longitudinal survey of anticardiolipin antibodies in systemic lupus erythematosus. Scand J Rheumatol 1992; 21: 271-276.
8. Comp PC. Congenital and acquired hypercoagulable states. In: Hull R, Pineo GF (eds) Disorders of Thrombosis. WB Saunders: Philadelphia, 1996, p 339.
9. Harris EN, Asherson RA, Hughes GRV. Antiphospholipid antibodies-autoantibodies with a difference. Annu Rev Med 1988; 39: 261.
10. Counts RB. A solid-phase immunoradiometric assay of factor VIII protein. Br J Haematol 1975; 31: 429.
11. Oosting JD, Derksen RHWM, Bobbink IWG et al. Anticardiolipin antibodies directed against a combination of phospholipids with prothrombin, protein C or protein S-an explanation for their pathogenic mechanism? Blood 1993; 81: 2618-2625.
12. Yin ET, Wessler S, Stoll PJ. Biological properties of the naturally occurring plasma inhibitor to activated factor X. J Biol Chem 1971; 246: 3703.
13. Blomback B, Hogg DH, Gardlund B et al. Fibrinogen and fibrin formation. Thromb Res 1976; 8: 329.
14. Ames PR, Alves J, Pap AF, Ramos P, Khamashta MA, Hughes GRV. Fibrinogen in systemic lupus erythematosus: more than an acute phase reactant? J Rheumatol 2000; 27: 1190-1195.
15. Asherson RA, Khamashta MA, Gil A et al. Cerebrovascular disease and antiphospholipid antibodies in systemic lupus erythematosus, lupus-like disease, and the primary antiphospholipid syndrome. Am J Med 1989; 86: 391-399.
16. Hess DC, Krauss J, Adams RJ, Nichols FT, Zhang D-I, Rountree HA. Anticardiolipin antibodies: A study of frequency in TIA and stroke. Neurology 1991; 41: 525-528.
17. Levine SR, Deegan MJ, Futrell N, Welch KMA. Cerebrovascular and neurologic disease associated with antiphospholipid antibodies: 48 cases. Neurology 1990; 40: 1181-1189.
18. The Antiphospholipid Antibodies in Stroke Study Group. Clinical and laboratory findings in patients with antiphospholipid antibodies and cerebral ischemia. Stroke 1990; 21: 1268-1273.
19. Yatsu FM. Other cerebrovascular syndrome. In: Rowland LP (ed) Merritt's Textbook of Neurology, 9th ed. Williams and Wilkins: New York, 1995, 257-262.
20. Petri M. Pathogenesis and treatment of the antiphospholipid antibody syndrome. Med Clin N Am 1997; 81: 151-177.
21. Wilson WA, Gharavi AE, Koike T et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report on an international workshop. Arthritis Rheum 1999; 42: 1309-1311.
22. Gharavi AE, Harris EN, Asherson RA, Hughes GRV. Anticardiolipin antibodies: isotype distribution and phospholipid specificity. Ann Rheum Dis 1987; 46: 1-6.
23. Harris EN, Gharavi AE, Patel SP, Hughes GRV. Evaluation of the anticardiolipin antibody test: report of an international workshop held 4th April 1986. Clin Exp Immunol 1987; 68: 215-222.
24. Exner T, Papadopoulos G, Koutts J. Use of a simplified dilute Russell's viper venom time (DRVVT) confirms heterogeneity among "lupus anticoagulants". Blood Coag Fibrinol 1990; 1: 259-266.
25. Zivelin A, Gitel S, Griffin JH et al. Extensive venous and arterial thrombosis associated with an inhibitor to activated protein C. Blood 1999; 94: 895-01.
26. Dykes AC, Walker ID, McMahon AD, Islam SI, Tait RC. A study of Protein S antigen levels in 3788 healthy volunteers: influence of age, sex and hormone use, and estimate for prevalence of deficiency state. Br J Haematol 2001; 113: 636-641.
27. Dunzendorfer S, Kaneider N, Rabensteiner A et al. Cell-surface heparan sulfate proteoglycan-mediated regulation of human neutrophil migration by the serpin antithrombin III. Blood 2001; 97: 1079-1085.
28. Balasubramanian V, Grusin NK, Bucher RW, Turitto VT, Slack SM. Residence-time dependent changes in fibrinogen adsorbed to polymeric biomaterials. J Biomed Mater Res 1999; 44: 253-260.
29. Hirsh J, Piovella F, Pini M. Congenital antithrombin III deficiency. Am J Med 1989; 87(S): 34S-38S.
30. Harris EN, Gharavi AE, Asherson RA, Boey ML, Hughes GRV. Cerebral infarction in systemic lupus erythematosus: association with anticardiolipin antibodies. Clin Exp Rheumatol 1984; 2: 47-51.
31. Montalban J, Rio J, Khamastha M et al. Value of immunologic testing in stroke patients. A prospective multicenter study. Stroke 1994; 25: 2412-2415.
32. Brey RL, Hart RG, Sherman DG, Tegeler CH. Antiphospholipid antibodies and cerebral ischemia in young people. Neurology 1990; 40: 1190-1196.
33. Chancellor AM, Glasgow GL, Ockelford PA, Johns A, Smith J. Etiology, prognosis, and hemostatic function after cerebral infarction in young adults. Stroke 1989; 20: 477-482.
34. Vaarala O, Alfthan G, Jauhiainen M et al. Cross reaction between antibodies to oxidized low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet 1993; 341: 923-925.
35. Kattwinkel N, Billanueva AG, Labib SB et al. Myocardial infarction caused by cardiac microvasculopathy in a patient with the primary antiphospholipid syndrome. Ann Intern Med 1992; 116: 974-976.
36. Hamsten A, Norberg R, Bjorkholm M, De Faire U, Holm G. Antibodies to cardiolipin in young survivors of myocardial infarction: an association with recurrent cardiovascular events. Lancet 1986; 1: 113-115.
37. Phadke KV, Phillips RA, Clarke DT, Jones M, Naish P, Carson P. Anticardiolipin antibodies in ischemic heart disease: marker or myth? Br Heart J 1993; 69: 391-394.
38. Ginsburg KS, Liang MH, Newcomer L et al. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 1992; 117: 997-1002.
39. Mateo J, Oliver A, Borrell M, Sala N, Fontcubetra J. Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism-results of the Spanish Multicentric Study on Thrombophilia (EMET-Study). Thromb Haemost 1997; 77: 444-451.
40. Zanon E, Prandoni P, Vianello F et al. Anti-beta2-glycoprotein I antibodies in patients with acute venous thromboembolism: prevalence and association with recurrent thromboembolism. Thromb Res 1999; 96: 269-274.
41. Love PE, Santoro SA. Antiphospholipid antibodies, anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Ann Intern Med 1990; 112: 682-689.
42. Ginsberg JS, Wells PS, Brill-Edwards P et al. Antiphospholipid antibodies and venous thromboembolism. Blood 1995; 86: 3685-3691.
43. Nencini P, Baruffi C, Abbate R, Massai G, Amaducci L, Inzitari D. Lupus anticoagulant and anticardiolipin antibodies in young adults with cerebral ischemia. Stroke 1992; 23: 189-193.
44. Hart RG, Miller VT, Coull BM, Bril V. Cerebral infarction associated with lupus anticoagulants: Preliminary report. Stroke 1984; 15: 114-118.
45. Hankey GJ, Eikelboom JW, van Bockxmeer FM et al. Inherited thrombophilia in ischemic stroke and its pathogenic subtypes. Stroke 2001; 32: 1793-1799.
46. Nojima J, Kuratsune H, Suehisa E et al. Association between the prevalence of antibodies to beta 2-glycoprotein I, prothrombin, protein C, protein S, and annexin V in patients with systemic lupus erythematosus and thrombotic and thrombocytopenic complications. Clin Chem 2001; 47: 1008-1015.
47. Ko GTC, Yeung VTF, Chan JCN et al. Plasma fibrinogen concentration in a Chinese population. Atherosclerosis 1997; 131: 211-217.
48. Asherson RA, Liote F, Page B et al. Avascular necrosis of bone and antiphospholipid antibodies in systemic lupus erythematosus. J Rheumatol 1993; 20: 284-287.
49. Seleznick MJ, Silveira LH, Espinoza LR. Avascular necrosis associated with anticardiolipin antibodies. J Rheumatol 1991; 18: 1416-1417.
50. Branch DW. Thoughts on the mechanism of pregnancy loss associated with the antiphospholipid syndrome. Lupus 1994; 3: 275-280.
51. Lynch A, Byers T, Emlen W, Rynes D, Shetterly SM, Hamman RF. Association of antibodies to beta2-glycoprotein 1 with pregnancy loss and pregnancy-induced hypertension: a prospective study in low-risk pregnancy. Obstet Gynecol 1999; 93: 193-198.
52. Simpson JL, Carson SA, Chesney C et al. Lack of association between antiphospholipid antibodies and first-trimester spontaneous abortion: prospective study of pregnancies detected within 21 days of conception. Fertil Steril 1998; 69: 814-820.
53. Teixido M, Font J, Reverter JC et al. Anti-beta 2-glycoprotein I antibodies: a useful marker for the antiphospholipid syndrome. Br J Rheumatol 1997; 36: 113-116.
54. Out HJ, Bruinse HW, Christiaens GCML et al. Prevalence of antiphospholipid antibodies in patients with fetal loss. Ann Rheum Dis 1991; 50: 553-557.
55. Asherson RA, Cervera R. The antiphospholipid syndrome. In: Lahita RG, Chiorazzi N, Reeves WH (eds) Textbook of the Autoimmune Diseases, 5th edition. Lippincott William & Wilkins: New York, 2000, 641-668.
56. Petri M. Clinical and management aspects of the antiphospholipid syndrome. In: Wallace DF, Hahn BH (eds). Dubois' Lupus Erythematosus, 5th edition. Williams & Wilkins: Baltimore, 1997, p 57.